地西他滨联合CAG预激方案治疗急性红白血病55例临床研究  

Efficacy of decitabine and CAG priming induction regimen in treatment of acute erythroleukemia

作　　者：张静人 刘跃均[1] 仇惠英[1] 胡晓慧[1] 徐杨[1] 桂晓敏[1] 金正明[1] 唐晓文[1] 韩悦[1] 陈苏宁[1] 孙爱宁[1] 吴德沛[1] 

机构地区：[1]苏州大学附属第一医院血液科江苏省血液研究所卫生部血栓与止血重点实验室,江苏苏州215006

出　　处：《中国实用内科杂志》2014年第11期1103-1105,共3页Chinese Journal of Practical Internal Medicine

基　　金："江苏省临床医学中心"资助(ZX201102);国家高科技研究发展计划(863计划)课题(2012AA02A505);江苏高校优势学科建设工程资助项目(PAPD);国家临床重点专科建设项目

摘　　要：目的探讨地西他滨联合CAG预激方案(阿克拉霉素+阿糖胞苷+粒细胞集落刺激因子)治疗急性红白血病的临床效果。方法回顾性分析2007年1月至2013年9月苏州大学附属第一医院55例初治AEL患者,其中23例采用预激方案治疗,19例采用标准方案化疗,13例使用地西他滨联合CAG方案。结果使用地西他滨联合CAG方案的患者缓解率达到61.5%,总反应率(ORR)92.3%,缓解率及反应率优于传统方案组及预激方案组患者,但差异无统计学意义。结论地西他滨可能在急性红白血病的临床治疗中取得较好效果。Objective To discuss the clinical efficacy of the treatment with Decitabine and CAG priming induction regimen for acute erythroleukemia（ AEL）. Methods Fifty-five cases of newly diagnosed AEL patients were included in this study.Twenty-three patients were treated with priming induction regimen,19 patients were treated with classical routine chemotherapy,and the other 13 patients were treated with decitabine combined with CAG regimen. Results After chemotherapy with decitabine and CAG regimen,the complete remission rate was 61. 5% and the overall response rate 92. 3%,which were higher than those after the classical chemotherapy and priming induction regimen therapy,but the difference was not statistically significant. Conclusion Decitabine may have a better efficacy in clinical treatment of acute erythroleukemia.

关 键 词：急性红白血病 骨髓增生异常综合征 遗传学改变 地西他滨 化疗方案 

分 类 号：R552[医药卫生—血液循环系统疾病]